DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Davidson - 3 Linda Bolton Weiser - 3 Eli Lilly - 2 Bolton Weiser - 2 Eli Lilly’s - 1 Brendan Mcdermid - 1 — - 1 Sima Sistani — - 1
Top related locs:
New York City U.S Herbalife University of North Carolina 2H23
Top related orgs:
CNBC - 3 pharma - 2 Novo Nordisk - 1 Craig - 1 University of North - 1 University of North Carolina Chapel - 1 ITT - 1 Gracell - 1

Search resuls for: "Linda Bolton Weiser"


6 mentions found


☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
  + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com   time to read: +6 min
In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.
Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina
☆ December's 'best-in-class' stocks include this obesity beneficiary, Wall Street analysts say
  + stars: | 2023-12-02 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
An obesity beneficiary and a snack foods company are just a few of the top stocks to buy in December, analysts said this week. Wall Street research firms named a slew of companies that they believe have upside heading into the years end. Obin said the company has a "preponderance" of margin tailwinds for 2024, including "differentiated auto exposure, underappreciated margin expansion opportunities, and best-in-class execution." "We are including BUY-rated EL in our research team's Best-of-Breed Bison initiative, which focuses on long-term best-in-class companies with sustainable competitive moats," analyst Linda Bolton Weiser said earlier this week. Estee Lauder — DA Davidson, buy rating "We are including BUY-rated EL in our research team's Best-of-Breed Bison initiative, which focuses on long-term best-in-class companies with sustainable competitive moats.
Persons: Estee Lauder, Gracell Biotechnologies, Eli Lilly, Andrew Obin, Obin, it's, Nik Modi, Modi, MDLZ, Mondelez, LSEG, Estee Lauder DA Davidson, Linda Bolton Weiser, Bolton Weiser, Gracell, Eli Lilly — Morgan Stanley, Estee Lauder —, Davidson Organizations: CNBC, ITT, Gracell, Bank of America, RBC, ISI, pharma, ITT — Bank of America
☆ Barbie is everywhere this summer. Here are the stocks that can benefit from the highly anticipated film
  + stars: | 2023-07-21 | by ( Alex Harring | ) www.cnbc.com   time to read: +8 min
But can the same be said for Mattel shares? Mattel stock is up more about 19% on a year to date basis after a mixed start to the year. Into the Barbie release, the stock reflects the growing buzz. Mattel shares moved from $17.59 on June 1 to breaking into the $20 range for the first time since February. Though Barbie is not a typical film in the space given its adult audience, Jefferies analyst Andrew Uerkwitz said, it can still help Mattel sales incrementally.
Persons: Gordon Haskett, Don Bilson, Greta Gerwig, Margot Robbie, Ryan Gosling, Bilson, Goldman Sachs, Stephen Laszczyk, Davidson, Linda Bolton Weiser, Bolton Weiser, Barbie, Brett Feldman, Jefferies, Andrew Uerkwitz, Roth, David Bellinger, Bellinger, Mario, Morgan Stanley, Benjamin Swinburne, ramped, Oppenheimer, Laszczyk, David Karnovsky, Karnovsky, — CNBC's Michael Bloom Organizations: Mattel, Warner Bros, Lions, Lions Gate, Hasbro, MAT, Analysts, Universal Pictures, Mario Bros, Hollywood, JPMorgan, CNBC, Alliance, Television Producers, Guild of America Locations: 2H23
☆ Hasbro warns of weak holiday quarter results
  + stars: | 2023-01-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHasbro warns of weak holiday quarter resultsLinda Bolton Weiser, senior analyst at D.A. Davidson, joins 'Closing Bell' to discuss Hasbro cutting 15% of its workforce, inventory issues facing toy producers, and more.
☆ Hasbro delivers dour quarter as higher prices cool demand
  + stars: | 2022-10-18 | by ( Granth Vanaik | ) www.reuters.com   time to read: +2 min
Oct 18 (Reuters) - Hasbro Inc (HAS.O) missed quarterly profit estimates on Tuesday as the company's move to raise prices to offset surging commodity costs led inflation-weary customers to buy fewer toys and games. "There is still indications of fairly strong demand for toys," Linda Bolton Weiser, analyst at D.A. Still, Hasbro saw its net revenue fall 15% to $1.68 billion in the third quarter ended Sept. 25, partly dented by a stronger dollar. Shares of the 'Magic: The Gathering' maker were down about 2% in morning trading. Register now for FREE unlimited access to Reuters.com RegisterReporting by Granth Vanaik in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.
☆ Analysts name the top 'high conviction' stocks for playing the market turbulence
  + stars: | 2022-09-24 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
CNBC Pro combed through top Wall Street research to find analysts' top "high conviction" ideas. With a Street high price target of $278, the stock is one of DA Davidson's top "high conviction" small cap ideas. DaVita The kidney and dialysis care provider was recently upgraded to a buy rating from neutral by investment firm UBS. UBS has a Street high price target of $117 per share, which implies a nearly 38% gain from the stock's current level. While a period of consolidation is possible, we have high conviction that CRWD is a unique investment vehicle as the modern security cloud, with exceptional long-term value creation potential."
0 next >>
Total: 6